Literature DB >> 21978874

New-onset postoperative atrial fibrillation predicts late mortality after mitral valve surgery.

Sander Bramer1, Albert H M van Straten, Mohamed A Soliman Hamad, Krista C van den Broek, Jos G Maessen, Eric Berreklouw.   

Abstract

BACKGROUND: New-onset postoperative atrial fibrillation (POAF) is a common rhythm disturbance after mitral valve surgery. In this study we investigated the independent effect of POAF on early and late mortality after mitral valve surgery.
METHODS: Data of patients who consecutively underwent mitral valve surgery with or without concomitant coronary or tricuspid valve surgery between January 2003 and June 2010 were prospectively collected. The study included 856 patients with preoperative sinus rhythm, and no history of atrial fibrillation. Logistic regression and Cox proportional hazard analyses were performed to investigate independent predictors of early and late mortality. Propensity score adjustment was performed to reduce the effect of confounders.
RESULTS: The median follow-up was 3.1 years (range, 0 to 7.4 years). The POAF was documented in 361 patients (42%). Early mortality did not differ in patients with and without POAF (p = 0.93). Postoperative atrial fibrillation was not identified as predictor for early mortality. Late survival was worse in patients with POAF (log-rank, p < 0.001). Multivariate and propensity score adjusted Cox proportional hazard analyses demonstrated that POAF was an independent predictor for late mortality with hazard ratios of 2.09 and 1.61 (p = 0.001 and p = 0.033, respectively).
CONCLUSIONS: Postoperative atrial fibrillation is an independent predictor for late all-cause mortality after mitral valve surgery but not for early all-cause mortality.
Copyright © 2011 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21978874     DOI: 10.1016/j.athoracsur.2011.06.079

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

Review 1.  Update in the Evaluation and Management of Perioperative Stroke.

Authors:  Dilip Kumar Jayaraman; Sandhya Mehla; Saurabh Joshi; Divya Rajasekaran; Richard P Goddeau
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

2.  Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery.

Authors:  Jawad Haider Butt; Jonas Bjerring Olesen; Anna Gundlund; Thomas Kümler; Peter Skov Olsen; Eva Havers-Borgersen; David Thein Aagaard; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Lars Køber; Emil Loldrup Fosbøl
Journal:  JAMA Cardiol       Date:  2019-11-01       Impact factor: 14.676

3.  CHADS2 and CHA2DS2-VASc scoring systems for predicting atrial fibrillation following cardiac valve surgery.

Authors:  Liang Yin; Xinyu Ling; Yufeng Zhang; Hua Shen; Jie Min; Wang Xi; Jing Wang; Zhinong Wang
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

4.  Abnormal heart rate variability and atrial fibrillation after aortic surgery.

Authors:  Leonida Compostella; Nicola Russo; Augusto D'Onofrio; Tiziana Setzu; Caterina Compostella; Tomaso Bottio; Gino Gerosa; Fabio Bellotto
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar

Review 5.  Short-term and Long-term Risk of Stroke in Patients With Perioperative Atrial Fibrillation After Cardiac Surgery: Systematic Review and Meta-analysis.

Authors:  Michael K Wang; Pascal B Meyre; Rachel Heo; P J Devereaux; Lauren Birchenough; Richard Whitlock; William F McIntyre; Yu Chiao Peter Chen; Muhammad Zain Ali; Fausto Biancari; Jawad Haider Butt; Jeff S Healey; Emilie P Belley-Côté; Andre Lamy; David Conen
Journal:  CJC Open       Date:  2021-09-16

Review 6.  Arrhythmias in Patients With Valvular Heart Disease: Gaps in Knowledge and the Way Forward.

Authors:  Maciej Kubala; Christian de Chillou; Yohann Bohbot; Patrizio Lancellotti; Maurice Enriquez-Sarano; Christophe Tribouilloy
Journal:  Front Cardiovasc Med       Date:  2022-02-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.